Abstract
The authors formulate criteria for an optimal pre-exposure prophylaxis drug candidate, and evaluate existing antiviral drug classes for their suitability.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anti-HIV Agents / therapeutic use
-
Anti-Retroviral Agents / economics
-
Anti-Retroviral Agents / standards*
-
Anti-Retroviral Agents / therapeutic use*
-
Clinical Trials as Topic*
-
Cost-Benefit Analysis
-
Drug Combinations
-
HIV Infections / prevention & control*
-
Humans
-
Lamivudine / therapeutic use
-
Research Design
Substances
-
Anti-HIV Agents
-
Anti-Retroviral Agents
-
Drug Combinations
-
Lamivudine